Tag Archives: drugmaker

At the bell: Starbucks, Amgen and Nash-Finch

Posted on November 10, 2011 by Martin Timble

In this report: Nash-Finch (NASDAQ:NAFC), Amgen (NASDAQ:AMGN) and Starbucks (NASDAQ:SBUX).

Nash-Finch (NASDAQ:NAFC) jumped more than 7 percent on Thursday after the company reported its third quarter financials. The food distributor seen net income drop by 34 percent during the period …

Posted in Latest Headlines, Reports | Tagged adjusted, Amgen, AMGN, analyst, biotech, Costco, deal, debt, demand, drugmaker, earnings, evilution fresh, finance, financials, industry, juice, money, NAFC, NASDAQ, NASDAQ:AMGN, NASDAQ:NAFC, NASDAQ:SBUX, Nash-Finch, net income, quarter, reinvent, report, repurchase, retailers, revenue, Safeway, sale, SBUX, SEC, sector, share, shares, Starbucks, stock, Whole Foods | Comments Off

What the Fuss Onyx Pharmaceuticals, Phillips-Van Heusen and Priceline.com?

Posted on October 12, 2011 by Cameron White

In this report: ONYX Pharmaceuticals Inc. (NASDAQ:ONXX), Phillips-Van Heusen (NYSE:PVH) and Priceline.com (NASDAQ:PCLN).

ONYX Pharmaceuticals Inc. (NASDAQ:ONXX) is trading more than 6.5 percent higher after the company settled its lawsuit against Bayer AG over its collaboration on the cancer drug …

Posted in Latest Headlines, Reports | Tagged agreed, analyst, Bayer AG, Buy, cancer drug, drugmaker, earnings, expect, firm, forecast, forecasted, initiation, Jefferies, lawsuit, NASDAQ, NASDAQ:ONXX, NASDAQ:PCLN, Nexavar, NYSE, NYSE:PVH, online travel agent, ONXX, ONYX Pharmaceuticals Inc., PCLN, Phillips-Van Heusen, price objective, Priceline.com, PVH, quarter, range, rates, rating, Regorafenib, trade, trading | Comments Off

Eli Lilly hit with high expenses in 2Q

Posted on July 21, 2011 by pmarek

Eli Lilly and Co. (NYSE:LLY) said thursday that higher marketing and research expenses lead the company to reporting an 11 percent drop in its second quarter earnings.

The drugmaker is gearing up for the launch of a type 2 diabetes …

Posted in Healthcare, Latest Headlines | Tagged analyst, budget, drugmaker, earnings, Eli Lilly, expenses, fiscal, forecast, LLY, marketing, NYSE:LLY, quarter, revenue, share | Comments Off

Valeant Pharma pay $345M for Janssen portfolio

Posted on July 15, 2011 by pmarek

Valeant Pharmaceuticals International announced on friday that it is set to acquire assets of the Ortho Dermatologics of Janssen Pharmaceuticals for $345 million.

The acquisition will see Canadian drugmaker Valeant Pharma take control of suchs prescription brands such as the …

Posted in Healthcare, Latest Headlines | Tagged acquire, assets, brands, drugmaker, Ertaczo, Janssen Pharmaceuticals, Ortho Dermatologics, portfolio, Renova, Retin-A-Micro, Valeant Pharmaceuticals | Comments Off

Bristol-Myers Squibb agrees deal to expand access to HIV treatment drug

Posted on June 28, 2011 by pmarek

Bristol-Myers Squibb (NYSE:BMY) announced on tuesday that they have given permission to a generic drugmaker to produce and sell its HIV treatment Reyataz in sub-Saharan Africa and India.

The healthcare giant said it has reached terms with Matrix Laboratories, a …

Posted in Healthcare, Latest Headlines | Tagged Africa, BMY, Bristol-Myers Squibb, company, didanosine, drugmaker, healthcare, HIV, India, Laboratories, Matrix, Mylan Pharmaceuticals, NYSE:BMY, pediatric, Reyataz, stavudine | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

Tag Archives: drugmaker

What the Fuss Onyx Pharmaceuticals, Phillips-Van Heusen and Priceline.com?

Valeant Pharma pay $345M for Janssen portfolio

Bristol-Myers Squibb agrees deal to expand access to HIV treatment drug

Follow us

Most Popular Posts

blogs